Osimertinib for Lung Cancer
This trial is studying osimertinib with or without bevacizumab for patients with EGFR positive non-small cell lung cancer that has spread to the brain.
- Non-Small Cell Lung Cancer (NSCLC)
- Brain Metastasis
- Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2020 Phase 4 trial • 60 Patients • NCT03853551
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there any analogous experiments involving Osimertinib?
"Currently, there are 450 trials exploring the effects of Osimertinib with 104 of them being in Phase 3. Many are concentrated around Taibei, Taiwan; however, it is being studied at over 21000 different locations world wide."
What is the current enrollment capacity for this experiment?
"At this point, the trial is not actively recruiting. It was first created on June 23rd 2017 and modified as recently as July 2nd 2022. For those seeking alternatives, there are 3946 clinical trials for carcinoma non-small cell lung cancer as well as 450 studies searching for Osimertinib participants currently accepting enrolment."
How does Osimertinib fare in terms of patient safety?
"The current level of safety data on osimertinib is assessed at 2, as the trial has reached Phase 2 but efficacy hasn't been fully established."
Are there still sign-up opportunities for this research project?
"As evidenced by clinicaltrials.gov, the recruitment process for this medical study has ended; initial posting was June 23rd 2017 and it was last updated on July 2nd 2022. Despite the conclusion of this trial's participant search, there are currently 4396 other trials that remain eager to find subjects for their research."
What diseases is Osimertinib typically employed to address?
"Primarily used to treat and manage malignant neoplasms, osimertinib has been successfully deployed in cases of recurrent platinum sensitive primary peritoneal cancer, stage IV epithelial ovarian cancer post-surgical resection, and locally advanced nonsquamous non-small cell lung cancers."
How widespread is the implementation of this experiment?
"This study is seeking participants at Ohio State University Comprehensive Cancer Center in Columbus, Ohio, Yale University in New Haven, Connecticut and Nebraska Medicine-Bellevue in Bellevue. Additionally there are 18 other potential sites that can be found on the trial's website."